Australia’s TGA published comments from industry, consumer and health professional groups on the proposed provisional approval registration process and post-market requirements for provisionally registered medicines. The public consultation paper sought written submissions from interested individuals and representatives.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
